Logo

AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval for the Treatment of Active Psoriatic Arthritis

Share this
AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval for the Treatment of Active Psoriatic Arthritis

AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval for the Treatment of Active Psoriatic Arthritis

Shots:

  • The approval is based on the 2 (KEEPsAKE-1 /2) studies evaluating Skyrizi (150mg, SC) vs PBO in adults with active PsA who had responded inadequately or were intolerant to biologic therapy & non-biologic DMARDs
  • The trial met the 1EPs i.e., @24wks., patients achieved the ACR20 response (57.3% & 51.3% vs 33.5% & 26.5%), improvements in ACR50, ACR70 responses, physical function, joint symptoms, improvements in other manifestations of PsA including dactylitis & enthesitis, skin lesions of psoriasis & the safety profile was consistent with patients with PsO
  • Skyrizi is an IL-23 inhibitor that blocks IL-23 by binding to its p19 subunit while P-III trials in psoriasis, CD, UC & PsA are ongoing

Ref: AbbVie | Image: abbvie

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions